Publication Name	World Journal of Gastroenterology
Manuscript ID	117396
Country	United States

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Roles of hepatic immunity in metabolic dysfunction-associated steatotic liver disease: Cellular and molecular mechanisms and clinical trials
Manuscript Source	Unsolicited Manuscript
All Author List	Ming Yang, Olamide T Olaoba, Stephanie C Chinwo, Hannah LeVasseur, Beiyan Zhou, Eric T Kimchi, Kevin F Staveley-O’Carroll and Guangfu Li
Funding Agency and Grant Number	Funding Agency Grant Number National Institutes of Health No. R01DK130340 National Institutes of Health No. R01CA274959 National Institutes of Health No. R01CA250536
Corresponding Author	Guangfu Li, PhD, Professor, Department of Surgery, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States. gli@uchc.edu
Key Words	Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Innate immune cells; Molecular mechanisms; Clinical trials; Drugs
Core Tip	Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad spectrum of pathology ranging from hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH). Effective treatments for MASLD remain limited. Hepatic innate immune cells play an essential role in maintaining liver physiological homeostasis and contributing to MASLD pathogenesis and progression by interacting with liver parenchymal cells and adaptive immune cells in the progression of MASLD and MASH. Treatments targeting innate immune cell manipulation and metabolic modulation, such as fibroblast growth factor 21 analogues, farnesoid X receptor agonists, and chemokine receptor antagonists, can provide therapeutic strategies for MASLD.
Citation	Yang M, Olaoba OT, Chinwo SC, LeVasseur H, Zhou B, Kimchi ET, Staveley-O’Carroll KF, Li G. Roles of hepatic immunity in metabolic dysfunction-associated steatotic liver disease: Cellular and molecular mechanisms and clinical trials. World J Gastroenterol 2026; In press

Received	2025-12-08 02:13
Peer-Review Started	2025-12-08 09:27
First Decision by Editorial Office Director	2025-12-18 10:05
Return for Revision	2025-12-18 10:05
Revised	2025-12-29 13:09
Publication Fee Transferred
Second Decision by Editor	2026-01-27 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-01-27 08:15
Articles in Press	2026-01-27 08:15
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com